AMMONUL (sodium phenylacetate and sodium benzoate) Injection 10% per 10% is supplied in a sterile, non-pyrogenic, single use glass vial.
NDC 0187-0010-50 single use vial containing 50 mL of sodium phenylacetate and sodium benzoate injection 10% per 10%.
Storage: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Physicians should advise patients and caregivers about the following for safe use of AMMONUL:
- When plasma ammonia levels have normalized, dietary protein intake can usually be increased with the goal of unrestricted protein intake.
- The most common adverse reactions are vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment.
- Generally BUPHENYL is stopped during the time AMMONUL is used.
Bausch Health US, LLC
Bridgewater, NJ 08807 USA
Cangene BioPharma, LLC
Baltimore, MD 21230 USA
AMMONUL is a trademark of Bausch Health Companies Inc. or its affiliates.
© 2020 Bausch Health Companies Inc. or its affiliates
(sodium phenylacetate and
sodium benzoate) injection
10% / 10%
- 50 mL For IV Use Only
Warning: Administration must be through a central venous catheter.
Administration through a peripheral line may cause burns.
Must be diluted before IV administration
Sterile, non-pyrogenic, single use vial
| AMMONUL |
sodium phenylacetate and sodium benzoate injection, solution, concentrate
|Labeler — Bausch Health US LLC (831922468)|
|Cangene bioPharma LLC||050783398||MANUFACTURE (0187-0010)|
Revised: 12/2020 Bausch Health US LLC
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.